Therma Bright Inc (TSXV: THRM) this morning announced that its development partner for its COVID-19 rapid saliva-based screening test has discovered a series of polypeptides that can be utilized for screening and detection of the COVID-19 virus. The discovery of the biological molecules assists in the further development of Therma Brights CoviSafe screening test.
The polypeptides are viewed as high-quality, which will assist in determining the presence of the COVID-19 virus over that of SARS or MERS which are similar biologically. The peptides discovered are said to “form the basis” of the testing currently being jointly developed by Therma Bright and Orpheus Medica.
Currently, Therma Bright intends to further validate the results through integration with the CoviSafe device, which is viewed as the next step in the development of the product. This additional validation of results is expected to occur in the “coming weeks.”
The peptides are said to lead to the firm providing additional test formats that will differentiate between the seasonal flu and COVID-19. The CoviSafe screening test is currently being developed to be utilized as a solution for routine and widespread testing for the virus, with the test being intended as a home kit, suitable for workplaces, sporting events, schools, and the home.
Therma Bright last traded at $0.14 on the TSX Venture.
Information for this briefing was found via Sedar and Therma Bright Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.